3) Both of selected drugs, Imatinib and Dasatinib, directly bind BCR-ABL kinase and inhibit the function of BCR-ABL in CML therapy, which reduced drugs-caused bias. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.